Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Results of an Open-Label Non-Randomized Clinical Trial: Response to David Spencer (Elsevier)
Raoult et al., Preprint (Preprint) (meta analysis)
Raoult et al., Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Results of an Open-Label Non-Randomized.., Preprint (Preprint) (meta analysis)
Jul 2020   Source   PDF  
  All Studies   Meta
Updated meta analysis showing significant reductions in mortality and viral shedding. Mortality OR 0.53 [0.4-0.71] for clinical studies, 0.92 big data studies, 18,211 patients. Persistent viral shedding OR 0.47 [0.28-0.79], 4,540 patients.
Currently there are 36 HCQ early treatment studies and meta analysis shows:
Mortality72% lower [57‑81%]
Ventilation67% lower [-710‑99%]
ICU admission28% lower [-17‑55%]
Hospitalization41% lower [28‑52%]
Raoult et al., 9 Jul 2020, preprint, 7 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: 1 Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Results of an 2 Open-Label Non-Randomized Clinical Trial: Response to David Spencer (Elsevier) 3 Didier Raoult1,2, Matthieu Million1,2, Philippe Gautret1,3, Jean-Christophe Lagier1,2, Philippe 4 Colson1,2, Philippe Parola1,3, and Jean-Marc Rolain1,2 5 Affiliations : 6 1 IHU-Méditerranée Infection, Marseille, France 7 2 Aix Marseille University, IRD, AP-HM, MEPHI, Marseille, France 8 3 Aix Marseille University, IRD, AP-HM, SSA, VITROME, Marseille, France 9 Corresponding author: Didier Raoult, IHU - Méditerranée Infection, 19-21 boulevard Jean 10 Moulin, 13005 Marseille, France. Tel.: +33 413 732 401, Fax: +33 413 732 402; email: 11 12 Key words: SARS-CoV-2; COVID-19; hydroxychloroquine; azithromycin 13 We thank the authors for the comments provided for our article (1-3), but we would like to 14 clarify key points for the story of this manuscript (4) that are critical in the context of COVID- 15 19 outbreak and for the perspective of this work. When COVID-19 starts around the world the 16 Editor-In-Chief of the Journal International Journal of Antimicrobial Agents (JM. Rolain) 17 asked colleagues (D. Raoult, PR. Hsueh, and S. Stefani) to launch a special issue in the 18 journal to create a real-time rapid debate around this emerging disease with special regards to 19 therapeutic options (5). Our preliminary paper (4) in this way was relatively trivial i.e 20 reported, in an emergency situation, a comparative analysis between a small group treated 21 with hydroxychloroquine and another small group not treated with hydroxychloroquine 22 showing a significant decrease of viral shedding after 6 days of therapy. 23 Surprisingly, despite the very small size of the group, the addition of azithromycin 24 made a difference on the endpoint we chose, which is the disappearance of the viral load in 25 the pharynx that is the only data that can be analyzed on a small group. Indeed, neither 26 mortality, nor the passage in intensive care unit, nor the duration of the treatment can be 27 evaluated on such a small group. This preliminary information was essential in our opinion 28 especially as it confirmed the preliminary in vitro and in vivo results against SARS-CoV-2 29 announced by the Chinese (6-8), also confirming previous in vitro reports on the anti-SARS- 30 CoV-1 coronavirus activity dating back to 2004 (9-12). This preliminary report paved the way 31 for work testing its reproducibility. 32 On the therapeutic level, the hydroxychloroquine + azithromycin combination was 33 found to be the most effective (4) consistent with in vitro synergistic antiviral activity 34 reported in our laboratory (13). Azithromycin had already, contrary to what one of the authors 35 says, been tested effectively on Zika (14,15), so we knew that it had an antiviral action. With 36 regard to our seminal paper on in vivo anti-SARS-CoV-2 activity of hydroxychloroquine (4), 37 we were subjected to unprecedented violence. I (DR) was asked to confess that I had a 38 relationship and a conflict of interest with Sanofi, which is laughable when you use generics 39 and you have had no relationship with the pharmaceutical industry at all at IHU (our center) 40 for 5 years. At the same time, the authors who published on remdesivir, for those we know, 41 the French, did not declare any conflict of interest in..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop